Orakle launches CME simulation on Niemann-Pick disease type C

Orakle has launched a new accredited CME activity designed to help clinicians recognize Niemann-Pick disease type C earlier through interactive virtual patient cases. The program goes live Aug. 29 and is aimed at reducing diagnostic delays in a rare neurodegenerative disorder that is often missed in children and adolescents.

Why it matters: - Niemann-Pick disease type C is a rare, progressive lysosomal disorder that is frequently diagnosed late because symptoms vary widely. - Earlier recognition can speed referral, testing and diagnosis for children and adolescents with suspected NPC. - The new format gives clinicians practice with real-world decision points instead of passive lecture content.

What happened: - Orakle announced The Detection and Diagnosis of Niemann–Pick Disease Type C, a new accredited, case-based CME activity. - The program is supported by an independent medical education grant from Zevra Therapeutics. - Clinicians can access the activity online at More information. - The activity becomes available Aug. 29, 2026, and remains accredited through Aug. 29, 2027.

The details: - The online course uses two interactive virtual patient encounters based on real-world diagnostic scenarios. - The simulations guide learners through age-dependent presentations, differential diagnosis, biomarker interpretation, genetic testing and referral decisions. - One case follows Daniel R., an adolescent with progressive neuropsychiatric decline. - The second case follows Maya R., a 4-year-old girl with hypotonia, developmental delay and splenomegaly. - Physicians who complete the activity can earn up to 1.00 AMA PRA Category 1 Credit™. - The target audience includes neurologists, pediatric neurologists, neurogeneticists, pediatricians, psychiatrists, ophthalmologists, geneticists and other clinicians involved in suspected NPC evaluations. - Orakle says the experience emphasizes active clinical decision-making and evolving patient presentations.

Between the lines: - Orakle is betting that simulation-based education can do more than transfer knowledge; it can train pattern recognition for rare diseases that clinicians may see only a few times, if at all, during a career. - The grant-funded model suggests industry-backed medical education remains a route for expanding awareness around underdiagnosed rare diseases. - The focus on pediatric and neuropsychiatric presentations signals where diagnostic delays may be most costly.

What's next: - Clinicians can begin taking the activity when it launches Aug. 29. - Orakle is positioning the program as part of a broader push to use immersive education to improve diagnostic speed and outcomes in rare disease care.

The bottom line: - Orakle’s new CME program turns NPC recognition into an interactive clinical exercise, aiming to help more clinicians spot the disease earlier and act faster.